• Perspective Therapeutics secured conference acceptance for interim safety and efficacy results from its [²¹²Pb]VMT-α-NET trial in advanced SSTR2-positive NETs.
• Findings will be presented Nov. 5 at the NANETS 2026 symposium in Las Vegas; earlier interim data were presented at ASCO in May 2026.
• Management is positioning the program as an alpha-emitting radiopharmaceutical option for patients with unresectable or metastatic disease who have not received prior RPT.
• Additional readouts from later cohorts remain pending, with more disclosures planned across 2026 and 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perspective Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070616PRIMZONEFULLFEED9841230) on October 07, 2026, and is solely responsible for the information contained therein.